Click for best price
Checkpoint Inhibitor Refractory Cancer Market Size, Share 2023
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitor Refractory Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitor Refractory Cancer. This report contains market size and forecasts of Checkpoint Inhibitor Refractory Cancer in global, including the following market information:
Global Checkpoint Inhibitor Refractory Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Checkpoint Inhibitor Refractory Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
PD-1 Inhibitors Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Checkpoint Inhibitor Refractory Cancer include Bristol-Myers Squibb, AstraZeneca, Merck, Roche, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Janssen Research and Development, 4D pharma and 4SC AG, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Checkpoint Inhibitor Refractory Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Checkpoint Inhibitor Refractory Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, by Type, 2022 (%)
PD-1 Inhibitors
PD-L1 Inhibitors
Global Checkpoint Inhibitor Refractory Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, by Application, 2022 (%)
Hodgkin Lymphoma
Kidney Cancer
Melanoma
Non-Small Cell Lung Cancer
Others
Global Checkpoint Inhibitor Refractory Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Checkpoint Inhibitor Refractory Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Checkpoint Inhibitor Refractory Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Checkpoint Inhibitor Refractory Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bristol-Myers Squibb
AstraZeneca
Merck
Roche
Regeneron Pharmaceuticals
Bristol-Myers Squibb
Janssen Research and Development
4D pharma
4SC AG
OncoSec Medical
Mirati Therapeutics
Ascentage Pharma Group
ENB Therapeutics
Exicure
Eisai
Kartos Therapeutics
Exelixis
ImmunityBio
Outline of Major Chapters:
Chapter 1: Introduces the definition of Checkpoint Inhibitor Refractory Cancer, market overview.
Chapter 2: Global Checkpoint Inhibitor Refractory Cancer market size in revenue.
Chapter 3: Detailed analysis of Checkpoint Inhibitor Refractory Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Checkpoint Inhibitor Refractory Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Checkpoint Inhibitor Refractory Cancer Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Checkpoint Inhibitor Refractory Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Checkpoint Inhibitor Refractory Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Checkpoint Inhibitor Refractory Cancer Overall Market Size
2.1 Global Checkpoint Inhibitor Refractory Cancer Market Size: 2022 VS 2029
2.2 Global Checkpoint Inhibitor Refractory Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Checkpoint Inhibitor Refractory Cancer Players in Global Market
3.2 Top Global Checkpoint Inhibitor Refractory Cancer Companies Ranked by Revenue
3.3 Global Checkpoint Inhibitor Refractory Cancer Revenue by Companies
3.4 Top 3 and Top 5 Checkpoint Inhibitor Refractory Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Checkpoint Inhibitor Refractory Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Checkpoint Inhibitor Refractory Cancer Players in Global Market
3.6.1 List of Global Tier 1 Checkpoint Inhibitor Refractory Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Checkpoint Inhibitor Refractory Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Checkpoint Inhibitor Refractory Cancer Market Size Markets, 2022 & 2029
4.1.2 PD-1 Inhibitors
4.1.3 PD-L1 Inhibitors
4.2 By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
4.2.1 By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
4.2.2 By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
4.2.3 By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Checkpoint Inhibitor Refractory Cancer Market Size, 2022 & 2029
5.1.2 Hodgkin Lymphoma
5.1.3 Kidney Cancer
5.1.4 Melanoma
5.1.5 Non-Small Cell Lung Cancer
5.1.6 Others
5.2 By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
5.2.1 By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
5.2.2 By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
5.2.3 By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Checkpoint Inhibitor Refractory Cancer Market Size, 2022 & 2029
6.2 By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue & Forecasts
6.2.1 By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2023
6.2.2 By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue, 2024-2029
6.2.3 By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.3.2 US Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.3.3 Canada Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.3.4 Mexico Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.4.2 Germany Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.3 France Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.4 U.K. Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.5 Italy Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.6 Russia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.4.8 Benelux Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.5.2 China Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.3 Japan Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.4 South Korea Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.5.6 India Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.6.2 Brazil Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.6.3 Argentina Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029
6.7.2 Turkey Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.3 Israel Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
6.7.5 UAE Checkpoint Inhibitor Refractory Cancer Market Size, 2018-2029
7 Checkpoint Inhibitor Refractory Cancer Companies Profiles
7.1 Bristol-Myers Squibb
7.1.1 Bristol-Myers Squibb Company Summary
7.1.2 Bristol-Myers Squibb Business Overview
7.1.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.1.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.2.4 AstraZeneca Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Merck
7.3.1 Merck Company Summary
7.3.2 Merck Business Overview
7.3.3 Merck Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.3.4 Merck Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.3.5 Merck Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.4.4 Roche Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Regeneron Pharmaceuticals
7.5.1 Regeneron Pharmaceuticals Company Summary
7.5.2 Regeneron Pharmaceuticals Business Overview
7.5.3 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.5.4 Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.5.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Company Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.6.4 Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.6.5 Bristol-Myers Squibb Key News & Latest Developments
7.7 Janssen Research and Development
7.7.1 Janssen Research and Development Company Summary
7.7.2 Janssen Research and Development Business Overview
7.7.3 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.7.4 Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.7.5 Janssen Research and Development Key News & Latest Developments
7.8 4D pharma
7.8.1 4D pharma Company Summary
7.8.2 4D pharma Business Overview
7.8.3 4D pharma Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.8.4 4D pharma Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.8.5 4D pharma Key News & Latest Developments
7.9 4SC AG
7.9.1 4SC AG Company Summary
7.9.2 4SC AG Business Overview
7.9.3 4SC AG Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.9.4 4SC AG Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.9.5 4SC AG Key News & Latest Developments
7.10 OncoSec Medical
7.10.1 OncoSec Medical Company Summary
7.10.2 OncoSec Medical Business Overview
7.10.3 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.10.4 OncoSec Medical Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.10.5 OncoSec Medical Key News & Latest Developments
7.11 Mirati Therapeutics
7.11.1 Mirati Therapeutics Company Summary
7.11.2 Mirati Therapeutics Business Overview
7.11.3 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.11.4 Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.11.5 Mirati Therapeutics Key News & Latest Developments
7.12 Ascentage Pharma Group
7.12.1 Ascentage Pharma Group Company Summary
7.12.2 Ascentage Pharma Group Business Overview
7.12.3 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.12.4 Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.12.5 Ascentage Pharma Group Key News & Latest Developments
7.13 ENB Therapeutics
7.13.1 ENB Therapeutics Company Summary
7.13.2 ENB Therapeutics Business Overview
7.13.3 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.13.4 ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.13.5 ENB Therapeutics Key News & Latest Developments
7.14 Exicure
7.14.1 Exicure Company Summary
7.14.2 Exicure Business Overview
7.14.3 Exicure Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.14.4 Exicure Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.14.5 Exicure Key News & Latest Developments
7.15 Eisai
7.15.1 Eisai Company Summary
7.15.2 Eisai Business Overview
7.15.3 Eisai Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.15.4 Eisai Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.15.5 Eisai Key News & Latest Developments
7.16 Kartos Therapeutics
7.16.1 Kartos Therapeutics Company Summary
7.16.2 Kartos Therapeutics Business Overview
7.16.3 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.16.4 Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.16.5 Kartos Therapeutics Key News & Latest Developments
7.17 Exelixis
7.17.1 Exelixis Company Summary
7.17.2 Exelixis Business Overview
7.17.3 Exelixis Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.17.4 Exelixis Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.17.5 Exelixis Key News & Latest Developments
7.18 ImmunityBio
7.18.1 ImmunityBio Company Summary
7.18.2 ImmunityBio Business Overview
7.18.3 ImmunityBio Checkpoint Inhibitor Refractory Cancer Major Product Offerings
7.18.4 ImmunityBio Checkpoint Inhibitor Refractory Cancer Revenue in Global Market (2018-2023)
7.18.5 ImmunityBio Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Checkpoint Inhibitor Refractory Cancer Market Opportunities & Trends in Global Market
Table 2. Checkpoint Inhibitor Refractory Cancer Market Drivers in Global Market
Table 3. Checkpoint Inhibitor Refractory Cancer Market Restraints in Global Market
Table 4. Key Players of Checkpoint Inhibitor Refractory Cancer in Global Market
Table 5. Top Checkpoint Inhibitor Refractory Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Checkpoint Inhibitor Refractory Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Checkpoint Inhibitor Refractory Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Checkpoint Inhibitor Refractory Cancer Product Type
Table 9. List of Global Tier 1 Checkpoint Inhibitor Refractory Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Checkpoint Inhibitor Refractory Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Checkpoint Inhibitor Refractory Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Checkpoint Inhibitor Refractory Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Checkpoint Inhibitor Refractory Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Checkpoint Inhibitor Refractory Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Bristol-Myers Squibb Company Summary
Table 31. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 32. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Bristol-Myers Squibb Key News & Latest Developments
Table 34. AstraZeneca Company Summary
Table 35. AstraZeneca Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 36. AstraZeneca Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. AstraZeneca Key News & Latest Developments
Table 38. Merck Company Summary
Table 39. Merck Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 40. Merck Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Merck Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 44. Roche Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. Regeneron Pharmaceuticals Company Summary
Table 47. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 48. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Regeneron Pharmaceuticals Key News & Latest Developments
Table 50. Bristol-Myers Squibb Company Summary
Table 51. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 52. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol-Myers Squibb Key News & Latest Developments
Table 54. Janssen Research and Development Company Summary
Table 55. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 56. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Janssen Research and Development Key News & Latest Developments
Table 58. 4D pharma Company Summary
Table 59. 4D pharma Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 60. 4D pharma Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. 4D pharma Key News & Latest Developments
Table 62. 4SC AG Company Summary
Table 63. 4SC AG Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 64. 4SC AG Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 65. 4SC AG Key News & Latest Developments
Table 66. OncoSec Medical Company Summary
Table 67. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 68. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 69. OncoSec Medical Key News & Latest Developments
Table 70. Mirati Therapeutics Company Summary
Table 71. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 72. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 73. Mirati Therapeutics Key News & Latest Developments
Table 74. Ascentage Pharma Group Company Summary
Table 75. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 76. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 77. Ascentage Pharma Group Key News & Latest Developments
Table 78. ENB Therapeutics Company Summary
Table 79. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 80. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 81. ENB Therapeutics Key News & Latest Developments
Table 82. Exicure Company Summary
Table 83. Exicure Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 84. Exicure Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 85. Exicure Key News & Latest Developments
Table 86. Eisai Company Summary
Table 87. Eisai Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 88. Eisai Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 89. Eisai Key News & Latest Developments
Table 90. Kartos Therapeutics Company Summary
Table 91. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 92. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 93. Kartos Therapeutics Key News & Latest Developments
Table 94. Exelixis Company Summary
Table 95. Exelixis Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 96. Exelixis Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 97. Exelixis Key News & Latest Developments
Table 98. ImmunityBio Company Summary
Table 99. ImmunityBio Checkpoint Inhibitor Refractory Cancer Product Offerings
Table 100. ImmunityBio Checkpoint Inhibitor Refractory Cancer Revenue (US$, Mn) & (2018-2023)
Table 101. ImmunityBio Key News & Latest Developments
List of Figures
Figure 1. Checkpoint Inhibitor Refractory Cancer Segment by Type in 2022
Figure 2. Checkpoint Inhibitor Refractory Cancer Segment by Application in 2022
Figure 3. Global Checkpoint Inhibitor Refractory Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Checkpoint Inhibitor Refractory Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Checkpoint Inhibitor Refractory Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Checkpoint Inhibitor Refractory Cancer Revenue in 2022
Figure 8. By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 16. US Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 28. China Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Checkpoint Inhibitor Refractory Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Checkpoint Inhibitor Refractory Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. AstraZeneca Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Regeneron Pharmaceuticals Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol-Myers Squibb Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Janssen Research and Development Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. 4D pharma Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. 4SC AG Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. OncoSec Medical Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Mirati Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Ascentage Pharma Group Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. ENB Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Exicure Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Eisai Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Kartos Therapeutics Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Exelixis Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. ImmunityBio Checkpoint Inhibitor Refractory Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
